# A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3

> **NCT01258101** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 395 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** peginterferon alfa-2a [Pegasys]
- **DRUG:** peginterferon alfa-2a [Pegasys]
- **DRUG:** ribavirin
- **DRUG:** ribavirin

## Key facts

- **NCT ID:** NCT01258101
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 395 (ACTUAL)
- **Last updated:** 2016-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01258101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01258101, "A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01258101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*